My top predictions for ASX lithium shares in 2023

Lithium miners are raking in cash at the moment. How could things go for the sector this year?

A bald man in a suit puts his hands around a crystal ball as though predicting the future.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Lithium miners are making very good profits with the elevated lithium price
  • The growing long-term demand for electric vehicles is positive for the sector
  • Miners already producing significant amounts of lithium are reaping the rewards

ASX lithium shares seem to be one of the market's most exciting sectors at the moment.

Between 23 June 2022 to 9 November 2022, the Pilbara Minerals Ltd (ASX: PLS) share price went up by around 170%.

However, Pilbara Minerals shares fell by 34% to 3 January 2023. Since 3 January, Pilbara Minerals shares have risen by more than 25%.

Other ASX lithium shares have seen similar patterns, including Allkem Ltd (ASX: AKE), Core Lithium Ltd (ASX: CXO), IGO Ltd (ASX: IGO), Sayona Mining Ltd (ASX: SYA), and Mineral Resources Ltd (ASX: MIN).

My thoughts on the lithium sector

Volatility is common on share markets. It doesn't surprise me when investors regularly shift between euphoria and fear on particular businesses. The wider share market occasionally goes through large bumps as well.

It makes sense that the lithium sector creates a lot of excitement. KPMG has estimated the world will need to manufacture more than two billion electrical vehicles to "accommodate world demand and fully transition away from internal combustion engine vehicles by 2050".

Of course, electric vehicles are just one use for lithium. Home batteries and large-scale batteries could increase demand too.

More supply is very likely to come online in the coming years, including the Mt Holland project that Wesfarmers Ltd (ASX: WES) is working on in Western Australia.

If lithium prices stay this high for longer, then it will drive more supply.

But it takes time for that supply to appear, so 2023 could still see a very healthy lithium price. Each ASX lithium share has its own customers, contracts, and method of selling its production.

For example, Pilbara Minerals is benefiting from increased prices from its major offtake customers, as well as a much higher price from the Battery Material Exchange (BMX) platform auctions compared to a year ago.

Strong cash flow and demand

I think that the businesses that are already producing lithium are in a really good place. They are producing enormous cash flow and are reaping the benefits. I think that strong cash flow will continue for (at minimum) the majority of the year.

In the three months to December 2022, we saw Pilbara Minerals increase its cash balance by $851 million.

Hopefully, the ones that aren't producing lithium at the moment will still get to reap the rewards of a good lithium price when they do start producing meaningful output.

In the latest Allkem quarterly update, it said that it expects the average price of lithium carbonate in the third quarter of FY23 to be in line with the second quarter. The ASX lithium share also pointed out:

EV sales growth is expected to remain robust in 2023 given strong order books and potential pent-up demand. Supportive government targets and policies announced globally (including subsidies or tax incentives) continue to ensure strong fundamentals for future growth.

Foolish takeaway

Overall, I think it could be a good year for the ASX lithium share sector as I don't think enough supply will come online this year to drive down the price substantially.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

a hand reaches out with australian banknotes of various denominations fanned out.
Dividend Investing

These 2 ASX dividend shares are great buys right now

These defensive names look like strong picks today.

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX 200 shares that could be top buys for growth

These two businesses have an exciting future.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

This ASX 200 share is being labelled one of the market's most undervalued by brokers

NextDC shares have pulled back sharply, but brokers believe the long-term growth story remains firmly on track.

Read more »

Hand holding out coal in front of a coal mine.
Energy Shares

Up 25% in 2025: Is Whitehaven Coal still a buy?

After a strong 25% run this year, investors are asking whether Whitehaven Coal still has more upside left.

Read more »

Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
Opinions

5 ASX shares I'd buy with $10,000 this week

These are the ASX stocks I have my eye on this week.

Read more »

bull market model with a bull looking at a rising chart
Opinions

By December 2026, $1,000 invested in EOS shares could be worth…

With its share price taking off and contracts piling up, EOS is shaping up as one of the most compelling…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »